Abstract: Aberrant accumulation of a specific sialic acid has been shown to exist in many human malignant cell membranes termed as N-glycolyl neuraminic acid (NeuGc). This particular ganglioside do not normally exist in normal human cells, due to the lack of an enzyme (cytidine monophospho-N-acetyl-neuraminic acid) which is responsible for the synthesis of N-glycolyl neurominic acid. The aberrant expression of NeuGcGM3 ganglioside in the cell surface of certain human tumors, made this molecule an attractive target for immunotherapy. By using 14F7 monoclonal antibody directed to identify NeugcgM3 in the tumor tissue, it is possible to select patients for anti-NeugcgM3 immunotherapy. racotumomab is an anti-idiotype vaccine, being a mirror image of Neugcgm3 mimics this ganglioside and triggers an immune response. Antibodies reactive to NeuGcGM3 ganglioside in the vaccinated patient's sera have cytotoxic anti-tumor properties which can be assessed in L1210 cell line, expressing this ganglioside.
Introduction
There is no expression of NeuGcGM3 ganglioside in normal human tissues, apart from minute amounts in brain tissue, due to the incapability of human cells synthesizing the N-glycoly neuraminic acid (Neugc). It is due to the lack of an enzyme which is responsible for the synthesis of this particular sialic acid in humans [1] . The aberrant antibody directed to identify NeugcgM3 in the tumor tissue, it is possible to select patients for anti-NeugcgM3 immunotherapy [2] . racotumomab is an anti-idiotype vaccine, being a mirror image of Neugcgm3 mimics this ganglioside and triggers an immune response. Antibodies reactive to NeugcgM3 ganglioside in the vaccinated patient's sera have cytotoxic anti-tumor properties which can be assessed in L1210 cell line, expressing this ganglioside [3] . Aberrant accumulation and over-expression of NeugcgM3 has been detected in human malignant tumors such as lung cancers, breast cancers, gliomas, urinary bladder tumors and hepatocellular cancers [4] . This aberrant expression of NeuGcGm3 is commonly detected in the surface of malignant cells, although cytoplasmic involvement was also reported. In a study, intense expression of this ganglioside in the periphery of nucleus was detected. Authors explained this finding as the possible synthesis of NeugcgM3 in the golgi apparatus and intracellular movement of this molecule within the cell [5, 6] .
There are numerous hypothesis explaining the existence of NeugcgM3 in human malignancies, from changing dietary habits to the modified metabolism of malignant cells as a result of genetic mutations, and due to the hypoxic conditions of tumor [7] . Yin and co-workers showed in their study that hypoxic conditions resulted in over expression of sialic acid transporter sialin, and induced cancer-associated gangliosides in human cancer cells [8] .
It was shown that, incorporation of NeugcgM3 into the cell membrane of T-lymphocytes down-regulates the CD4 expression and interfere in the functions of both CD4 and CD25 T-lymphocytes along with dendritic cells [9] .
Conclusively, these factors could lead to tumor-induced suppression by inhibiting the specific immune response. NeuGcGM3 is capable to bind to the extracellular domain of the epidermal growth factor receptor (egFr). This binding may provoke egFr system activation mediated by the epidermal growth factor ligand (egF). Activation of EGF in the presence of over expressed NeuGcGM3 constitutes a more aggressive immunophenotype in nonsmall cell lung cancer (NsCLC) [10] . Combination of antiegF plus anti-NeugcgM3 immunotherapies are currently under investigation [11] . Abnormal accumulation of Neugcgm3 in selected human malignant tumor cells, made this molecule an attractive target for cancer immunotherapy, minimizing the risk of potential damage to healthy tissues, since normal human cells do not carry this ganglioside [12] . The immunostaining with the 14F7 Igg1 monoclonal antibody is a highly specific tool for the detection of NeugcgM3 ganglioside in the tumor tissue. The immunohistochemical detection of NeugcgM3, allows the potential selection of patients for specific therapy with anti-idiotype racotumomab cancer vaccine [3] . racotumomab is an anti-idiotypic monoclonal antibody raised against NeugcgM3 in combination with aluminum hydroxide, as an adjuvant. Alum enhances the production of antibodies, stimulates monocytes to produce proimflammatory cytokines, and slower the release of antigen from the injection site [13, 14] .
The production process of racotumomab anti-idiotypic mouse monoclonal antibody, involves the immunization of Balb/c mice with NeugcgM3 ganglioside, followed by isolation of IgM monoclonal antibody (Ab1). This Ab1 antibody was again used in mice to generate an Igg1 monoclonal antibody (Ab2) later named as racotumomab which has a high affinity towards Ab1 idiotype ( Figure  1) . Antibodies reactive to NeugcgM3 ganglioside in the vaccinated patient's sera have cytotoxic anti-tumor properties which can be monitored in L1210 cell line expressing this ganglioside.
In human healthy donors, it was found that naturally occurring antibodies against NeugcgM3 are able to recognize and kill tumor cells expressing this antigen [15] .
Antibodies reactive to NeugcgM3 ganglioside in the vaccinated patient's sera have cytotoxic anti-tumor properties which can be enumerated in L1210 cell line expressing this ganglioside [3] . In this study, we monitored 
Materials and methods

Study design and selection of patients
The primary end point of the study was to investigate the value of serum anti-NeuGcGM3 antibodies and cytotoxic tests (cytotoxic properties of vaccinated patients' sera in cell culture) as biomarkers of treatment efficacy or failure.
We also investigated the value of these two markers in connection with progression free survival. The secondary centers (ANADOLU health Center, KOC University, ege University and ACIBADeM University). however, all the lab work, including antibody detection, tissue Neugcgm3 expression and cytotoxic tests with patients' sera were performed at ANADOLU Health Center. Cytotoxic tests from the same seras' were repeated at MeDIPOL University, for confirmation. In case of a conflicting result, tests were run for the 3rd time, in each institution, until reconciliation has been reached. The immunostaining was performed with the 14F7 monoclonal antibody in all patients' tumor tissue.
Laboratory Analysis Immunohistochemistry
For the detection of expression of NeuGcGM3 in the tumor paraffin blocks, the murine monoclonal antibody 14 F7 was used. This antibody was obtained from mice that were immunized with purified gangliosides and supplied by the manufacturer institute (CIM-Center of Molecular Immunology, havana, Cuba). Detection of the ganglioside in the tumor tissue was done by immunohistochemistry (IhC) with 20 µg/mL, biotinylated anti-Igg immune serum and a streptavidin-peroxidase commercial kit that uses diaminobenzidine as a peroxidase substrate. Immunoreactivity on the sample was evidenced as a brown staining. 5µm-thick sections of tissue was used to observe the expression of NeuGcGM3 [6] .
Cytotoxicity test
Antibodies to NeuGcGM3 have been detected and cytotoxic tests was done with hyperimmune patient's sera in L1210 cell lines expressing N-Glycol GM3, using BD FACS Calibur Flow Cytometry System, BD influx flow machine and BD FACs software, at the time of initiation (day zero), and at the 3 rd , 6 th , 9 th and 12 th months of vaccination.
Both pre-immune and hyperimmune patients' sera were incubated with the L1210 murine lymphocytic leukemia cell line. The L1210 murine lymphocytic leukemia cell line expressing high levels of NeuGcGM3 was provided from ATCC (American Type Culture Collection Co.). Cells were grown in DMeM medium supplemented with 10% of heat-inactivated fetal bovine serum (gibco), 2 mmol/L L-glutamine and maintained at 37ºC for 3 h. To determine the cell death (cell-kill) percentage, propidium iodine (PI; sigma, Aldrich) was used at a final concentration of 10/ mL cytotoxicity was evaluated by flow cytometry using the PI exclusion assay. This assay was also repeated with normal controls sera. Cytotoxic activity over cut off value of 30% increased cell kill compared to basal level (day 0 preimmune sera), when available, or against negative control (healthy donor's sera) considered positive. Cells without immune sera (cell alone) were also used as a double negative control. Results of cytotoxic tests as a prognostic tool and clinical outcome of the patients were compared. The assessment of the potential predictive value of NeuGcGM3 expressions in the tumor tissue for efficacy outcomes was also investigated.
Scanning electron microscopy
scanning electron microscopy (Zeiss sigma 500) photographs of antibody induced apoptosis in L1210 cell culture were performed at 9 eYLUL University Institutes of Biomedicine and genom. For the preparation of cells to electron microscopic photographing, L1210 cells in 100 mL rPMI 1640 culture medium supplemented with 1% fetal calf serum (FCs) were incubated with patients' sera for 2 h at 37ºC, washed three times with PBS, and then fixed with 3.2% glutaraldehyt in 0.1 mol/L sodium phosphate buffer (pH 7.4) at 4ºC for 1 h. These cells were postfixed for 1h in 1% OsO4, washed three times with phosphate buffer saline (PBs), and dehydrated in ethyl alcohol. Cells were mounted onto a metallic stub and coated (Quorum Q150r) with 5 nm thick gold before analyzed by Zeiss Sigma 500.
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Results
Out of 12 patients, 11 were male and one female. The mean age was 61 (47-68). eCOg performance status was 0-2. Out of 12 patients, 11 patients' sera showed positive cytotoxic activity over cut off value, in NeuGcGM expressing L1210 cell line. Mean progression free survival (PFs) for these patients was 13. Best cytotoxic responses to patients' immune sera, treated with racotumomab occurred at the 6 th and 9 th month of vaccination, approximately between 9 to 12 intradermal application of racotumomab (Figure 4 and Figure 5 ). In summary, 75% of the vaccinated patients showed progressively increased cell kill in their consecutive assays and all these patients are clinically, in stable condition. Two patients who progressed showed reduced cell kill in their consecutive assays despite continuing vaccination. however, one of these patients progressed after dis con tinu a tion of racotumoab. This patient's cytotoxic test results were positive until 15 th month when he decided not to take the vaccine. electron microscopic photographs of cellular swelling and the formation of membrane gaps due to the loss of cell membrane integrity in the culture is a proof of oncotic necrosis induced by Anti-NeugcgM3 antibody (Figure 6) A specific anti-N-glycolyl-GM3 response was observed, and weak antibody titers detected to mainly Igg and, few to IgM almost in all patients (10 out of 12). however, only 2 patients' antibody titers elevated beyond cut off levels which was considered to be positive (patients 5 and 11). The best antibody response was reached at the 8 th and 10 th dose of vaccination. These patients also showed parallel cell kill result at the cell culture. however apart from these two patients, there were no correlation between cytotoxic tests and antibody response and clinical status of patients in others.
We also looked for potential predictive value of NeuGcGM3 expression intensity in the tumor tissue for efficacy outcome. however, there was no significant A B Figure 6 . Oncotic necrosis process: scanning electron microscopy (A) Oncotic necrosis process with hyperimmune sera in L1210 cell culture (B) Preimmune sera-negative control 229 difference in between IhC staining intensities with 14F monoclonal antibody in terms of cytotoxicity results. L1210 cells in 100 mL rPMI 1640 culture medium supplemented with 1% FCs were incubated with patients' sera for 2 h at 37˚C, washed three times with PBS, and then fixed with 3.2% glutaraldehyde in 0.1 mol/L sodium phosphate buffer (pH 7.4) at 4˚C for 1 h. These cells were postfixed for 1 h in 1% OsO4, washed three times with PBs, and dehydrated in ethyl alcohol. Cells were mounted onto a metallic stub and coated (Quorum Q150r) with 5 nm thick gold before analyzed by Zeiss Sigma 500. (9 eYLUL University Institutes of Biomedicine and genom).
Discussion
According to the idiotypic network theory proposed by Jerne, it is possible to induce an immune response against an antigenic epitope using anti-idiotype antibody. This is due to the fact that these antigens have the capacity of mimicking the original antigen [16] . Anti-idiotype antibodies (anti-id abs) see other antibodies as the antigen and bind to it. They are antibodies to idiotopes, located in the antigen binding site of another antibody. These anti-id abs can act as surrogates of the original antigen. Modulation of immune response by these anti-id abs, attracted the attention of researchers for the development of anti-id vaccines against tumor associated antigens. Hernandez et al. demonstrated that, patients vaccinated with racotumomab produced antibodies to NeuGcGm3.When immunized patients' sera exposed to tumor cells in the culture expressing NeuGcGm3, majority of the cells were killed. According to authors, this cytotoxic effect was different from apoptosis because caspases were not involved. There were no complement activity and the process was fast with the destruction of cytoskeleton. They termed this process as oncotic necrosis [17] . Neugcgm3 ganglioside-based vaccines have been tested in several Phase II-III studies in nonsmall cell lung cancer and melanoma [18] [19] [20] [21] . racotumomab is currently registered in Cuba and Argentina in nonsmall cell lung cancer as a second line treatment after first line chemotherapy. In a multicenter double-blind, randomized, placebo controlled trial involving 350 patients with advanced NsCLC, Alphonso et al. demonstrated an overall survival benefit, almost doubled in one year (28% vs. 48%) and tripled in 2 years (28% vs. 8%) favoring the study group [20] . In their study, serum antiNeugcgM3 antibodies had been monitored which showed increasing titers with successive doses in the patient with survival benefit. Peak antibody levels were reached after the 6 th or 7 th dose of vaccination and remained stable for several months. They also performed cytotoxic tests with immunized patients' sera in L1210 cell lines expressing NeugcgM3 ganglioside and demonstrated a profound cell kill which they termed as oncolysis [20] . however, these tests and tumor tissue ganglioside expression were not used as biomarkers neither to predict treatment outcomes nor for the selection of the right patient who will benefit most from the vaccine. 
Conclusion
Although one may argue about the positive selection bias of our patients for the cytotoxic tests (stable or responder patients to chemo, and selection of the patients with positive reaction to 14F7 antibody in the tumor tissue), we can claim that cytotoxic test results predict prognosis. When the percentage of cell kill progressively increases in L1210 cell culture in consecutive assays with immune patient's sera we can predict a better outcome, looking to the longer PFs of these patients. This study meets the primary goal of the investigation which was to investigate the value of cytotoxic test as a biomarker for treatment outcome. Our observation confirmed that, consistently higher cytotoxicity rates in the cell culture correlated with better progression free survivals of the patients who are on racotumomab maintenance.
In our assay, anti-body responses have been weak and have not been correlated with cytotoxic tests and clinical status, apart from aforementioned two patients. This may well be due to undetected technical reasons and currently under investigation in cooperation with Cuban and Argentinian scientists who are pioneers in the development of anti-NuegcgM3 treatment strategies and conductors of Phase I-III clinical trials with racotumomab. In this study, we could not assess the potential predictive value of NeuGcGM3 expression in the tumor tissue for efficacy outcome, since there was no significant difference in between IhC staining intensities with 14F monoclonal antibody in terms of cytotoxicity results. However, the issue of NeuGcGM3 expression in the tumor tissue as a biomarker deserves further investigation.
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